AKT1 and breast cancer: The PI3K‒AKT pathway, autophagy, and alterations in metabolism can all contribute to TAM resistance in BC, and PI3K‒AKT pathway inhibitors have been approved for treatment of endocrine therapy-refractory BC patients.